Organization
Deutsches Zentrum Immuntherapie
2 abstracts
Abstract
Breaking primary checkpoint inhibitor resistance: Interim analysis of a multicenter phase II study by intermittent application of an alkylating agent among patients with metastatic melanoma.Org: Department of Dermatology, Ludwig-Maximilians-Universität München, University Hospital Regensburg, University Hospital Würzburg, Universitätsklinikum Erlangen,
Abstract
Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma.Org: University Hospital Essen, University Hospital Zurich, Melanoma Institute Australia, University Hospital Heidelberg, Universitaetsklinikum Erlangen,